Steven Daniel Schwartz, Director at Avalanche Biotechnologies, Inc. (AAVL), sold 17,250 shares at $40.38 ($685K) on 2015-04-09, disclosed to the SEC on 2015-04-13.
Scheduled sale ($685k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $39.72 | 17,050 | $677K | 98.8% |
| 2 | $40.38 | 200 | $8K | 1.2% |
| Total | $39.73 avg | 17,250 | $685K | 100% |
| Filing → |
| AAVL | SELL | 2015-05-22 | $648K | — | Filing → |
| AAVL | SELL | 2015-05-11 | $570K | — | Filing → |
| AAVL | SELL | 2015-04-23 | $652K | — | Filing → |